Turnidge John D, Gottlieb Thomas, Mitchell David H, Coombs Geoffrey W, Daly Denise A, Bell Jan M
Microbiology and Infectious Diseases, SA Pathology, Women's and Children's Hospital, North Adelaide, South Australia and Departments of Pathology, Paediatrics and Molecular Biosciences, University of Adelaide, South Australia.
Department of Microbiology and Infectious Diseases, Concord, Concord, New South Wales.
Commun Dis Intell Q Rep. 2014 Mar 31;38(1):E54-8. doi: 10.33321/cdi.2014.38.11.
The Australian Group on Antimicrobial Resistance performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2012 survey focussed on community-onset infections, examining isolates from urinary tract infections from patients presenting to outpatient clinics, emergency departments or to community practitioners. In 2012, 2,025 Escherichia coli, 538 Klebsiella species and 239 Enterobacter species were tested using a commercial automated method (Vitek 2, BioMérieux) and results were analysed using Clinical and Laboratory Standards Institute breakpoints from January 2012. Of the key resistances, non-susceptibility to the third-generation cephalosporin, ceftriaxone, was found in 4.2% of E. coli and 4.6%-6.9% of Klebsiella spp. Non-susceptibility rates to ciprofloxacin were 6.9% for E. coli, 0.0%-3.5% for Klebsiella spp. and 0.8%-1.9% in Enterobacter spp, and resistance rates to piperacillin-tazobactam were 1.7%, 0.7%-9.2%, and 8.8%-11.4% for the same 3 groups respectively. Only 1 Enterobacter cloacae was shown to harbour a carbapenemase (IMP-4).
澳大利亚抗菌药物耐药性研究小组定期开展时期患病率研究，以监测特定肠道革兰氏阴性病原菌的抗菌药物耐药性变化。2012年的调查聚焦于社区获得性感染，检测了来自门诊诊所、急诊科或社区医生处就诊患者的尿路感染分离株。2012年，使用商业自动化方法（Vitek 2，生物梅里埃公司）对2025株大肠杆菌、538株克雷伯菌属和239株肠杆菌属进行了检测，并采用2012年1月起的临床和实验室标准协会的断点对结果进行分析。在主要耐药情况中，4.2%的大肠杆菌和4.6%-6.9%的克雷伯菌属对第三代头孢菌素头孢曲松不敏感。大肠杆菌对环丙沙星的不敏感率为6.9%，克雷伯菌属为0.0%-3.5%，肠杆菌属为0.8%-1.9%，这三组对哌拉西林-他唑巴坦的耐药率分别为1.7%、0.7%-9.2%和8.8%-11.4%。仅1株阴沟肠杆菌被证明携带碳青霉烯酶（IMP-4）。
